Standard

Thirteen weeks of supplementation of vitamin D and leucine-enriched whey protein nutritional supplement attenuates chronic low-grade inflammation in sarcopenic older adults: the PROVIDE study. / Liberman, Keliane; Njemini, Rose; Luiking, Yvette; Forti, Louis N.; Verlaan, Sjors; Bauer, Juergen M.; Memelink, Robert; Brandt, Kirsten; Donini, Lorenzo M.; Maggio, Marcello; Mets, Tony; Wijers, Sander L. J.; Sieber, Cornel; Cederholm, Tommy; Bautmans, Ivan.

In: Aging Clinical and Experimental Research, Vol. 31, No. 6, 06.2019, p. 845-854.

Research output: Contribution to journalArticleResearchpeer-review

Harvard

Liberman, K, Njemini, R, Luiking, Y, Forti, LN, Verlaan, S, Bauer, JM, Memelink, R, Brandt, K, Donini, LM, Maggio, M, Mets, T, Wijers, SLJ, Sieber, C, Cederholm, T & Bautmans, I 2019, 'Thirteen weeks of supplementation of vitamin D and leucine-enriched whey protein nutritional supplement attenuates chronic low-grade inflammation in sarcopenic older adults: the PROVIDE study' Aging Clinical and Experimental Research, vol. 31, no. 6, pp. 845-854. https://doi.org/10.1007/s40520-019-01208-4

APA

Vancouver

Author

Liberman, Keliane ; Njemini, Rose ; Luiking, Yvette ; Forti, Louis N. ; Verlaan, Sjors ; Bauer, Juergen M. ; Memelink, Robert ; Brandt, Kirsten ; Donini, Lorenzo M. ; Maggio, Marcello ; Mets, Tony ; Wijers, Sander L. J. ; Sieber, Cornel ; Cederholm, Tommy ; Bautmans, Ivan. / Thirteen weeks of supplementation of vitamin D and leucine-enriched whey protein nutritional supplement attenuates chronic low-grade inflammation in sarcopenic older adults: the PROVIDE study. In: Aging Clinical and Experimental Research. 2019 ; Vol. 31, No. 6. pp. 845-854.

BibTeX

@article{a55de4f155864b6ca18948ef2c838bab,
title = "Thirteen weeks of supplementation of vitamin D and leucine-enriched whey protein nutritional supplement attenuates chronic low-grade inflammation in sarcopenic older adults: the PROVIDE study",
abstract = "Background: A chronic low-grade inflammatory profile (CLIP) is associated with sarcopenia in older adults. Protein and Vitamin (Vit)D have immune-modulatory potential, but evidence for effects of nutritional supplementation on CLIP is limited. Aim: To investigate whether 13 weeks of nutritional supplementation of VitD and leucine-enriched whey protein affected CLIP in subjects enrolled in the PROVIDE-study, as a secondary analysis. Methods: Sarcopenic adults (low skeletal muscle mass) aged ≥ 65 years with mobility limitations (Short Physical Performance Battery 4–9) and a body mass index of 20–30 kg/m 2 were randomly allocated to two daily servings of active (n = 137, including 20 g of whey protein, 3 g of leucine and 800 IU VitD) or isocaloric control product (n = 151) for a double-blind period of 13 weeks. At baseline and after 13 weeks, circulating interleukin (IL)-8, IL-1 receptor antagonist (RA), soluble tumor-necrosis-factor receptor (sTNFR)1, IL-6, high-sensitivity C-reactive protein, pre-albumin and 25-hydroxyvitamin(OH)D were measured. Data-analysis included repeated measures analysis of covariance (corrected for dietary VitD intake) and linear regression. Results: IL-6 and IL-1Ra serum levels showed overall increases after 13 weeks (p = 0.006 and p < 0.001, respectively). For IL-6 a significant time × treatment interaction (p = 0.046) was observed, with no significant change over time in the active group (p = 0.155) compared to control (significant increase p = 0.012). IL-8 showed an overall significant decrease (p = 0.03). The change in pre-albumin was a significant predictor for changes in IL-6 after 13 weeks. Conclusions: We conclude that 13 weeks of nutritional supplementation with VitD and leucine-enriched whey protein may attenuate the progression of CLIP in older sarcopenic persons with mobility limitations.",
keywords = "Aged, Aged, 80 and over, Dietary Supplements, Double-Blind Method, Female, Humans, Interleukin 1 Receptor Antagonist Protein/blood, Interleukin-6/blood, Leucine/pharmacology, Male, Middle Aged, Mobility Limitation, Muscle, Skeletal/drug effects, Sarcopenia/blood, Vitamin D/pharmacology, Whey Proteins/pharmacology",
author = "Keliane Liberman and Rose Njemini and Yvette Luiking and Forti, {Louis N.} and Sjors Verlaan and Bauer, {Juergen M.} and Robert Memelink and Kirsten Brandt and Donini, {Lorenzo M.} and Marcello Maggio and Tony Mets and Wijers, {Sander L. J.} and Cornel Sieber and Tommy Cederholm and Ivan Bautmans",
year = "2019",
month = "6",
doi = "10.1007/s40520-019-01208-4",
language = "English",
volume = "31",
pages = "845--854",
journal = "Aging Clinical and Experimental Research",
issn = "1594-0667",
publisher = "Springer Verlag",
number = "6",

}

RIS

TY - JOUR

T1 - Thirteen weeks of supplementation of vitamin D and leucine-enriched whey protein nutritional supplement attenuates chronic low-grade inflammation in sarcopenic older adults: the PROVIDE study

AU - Liberman, Keliane

AU - Njemini, Rose

AU - Luiking, Yvette

AU - Forti, Louis N.

AU - Verlaan, Sjors

AU - Bauer, Juergen M.

AU - Memelink, Robert

AU - Brandt, Kirsten

AU - Donini, Lorenzo M.

AU - Maggio, Marcello

AU - Mets, Tony

AU - Wijers, Sander L. J.

AU - Sieber, Cornel

AU - Cederholm, Tommy

AU - Bautmans, Ivan

PY - 2019/6

Y1 - 2019/6

N2 - Background: A chronic low-grade inflammatory profile (CLIP) is associated with sarcopenia in older adults. Protein and Vitamin (Vit)D have immune-modulatory potential, but evidence for effects of nutritional supplementation on CLIP is limited. Aim: To investigate whether 13 weeks of nutritional supplementation of VitD and leucine-enriched whey protein affected CLIP in subjects enrolled in the PROVIDE-study, as a secondary analysis. Methods: Sarcopenic adults (low skeletal muscle mass) aged ≥ 65 years with mobility limitations (Short Physical Performance Battery 4–9) and a body mass index of 20–30 kg/m 2 were randomly allocated to two daily servings of active (n = 137, including 20 g of whey protein, 3 g of leucine and 800 IU VitD) or isocaloric control product (n = 151) for a double-blind period of 13 weeks. At baseline and after 13 weeks, circulating interleukin (IL)-8, IL-1 receptor antagonist (RA), soluble tumor-necrosis-factor receptor (sTNFR)1, IL-6, high-sensitivity C-reactive protein, pre-albumin and 25-hydroxyvitamin(OH)D were measured. Data-analysis included repeated measures analysis of covariance (corrected for dietary VitD intake) and linear regression. Results: IL-6 and IL-1Ra serum levels showed overall increases after 13 weeks (p = 0.006 and p < 0.001, respectively). For IL-6 a significant time × treatment interaction (p = 0.046) was observed, with no significant change over time in the active group (p = 0.155) compared to control (significant increase p = 0.012). IL-8 showed an overall significant decrease (p = 0.03). The change in pre-albumin was a significant predictor for changes in IL-6 after 13 weeks. Conclusions: We conclude that 13 weeks of nutritional supplementation with VitD and leucine-enriched whey protein may attenuate the progression of CLIP in older sarcopenic persons with mobility limitations.

AB - Background: A chronic low-grade inflammatory profile (CLIP) is associated with sarcopenia in older adults. Protein and Vitamin (Vit)D have immune-modulatory potential, but evidence for effects of nutritional supplementation on CLIP is limited. Aim: To investigate whether 13 weeks of nutritional supplementation of VitD and leucine-enriched whey protein affected CLIP in subjects enrolled in the PROVIDE-study, as a secondary analysis. Methods: Sarcopenic adults (low skeletal muscle mass) aged ≥ 65 years with mobility limitations (Short Physical Performance Battery 4–9) and a body mass index of 20–30 kg/m 2 were randomly allocated to two daily servings of active (n = 137, including 20 g of whey protein, 3 g of leucine and 800 IU VitD) or isocaloric control product (n = 151) for a double-blind period of 13 weeks. At baseline and after 13 weeks, circulating interleukin (IL)-8, IL-1 receptor antagonist (RA), soluble tumor-necrosis-factor receptor (sTNFR)1, IL-6, high-sensitivity C-reactive protein, pre-albumin and 25-hydroxyvitamin(OH)D were measured. Data-analysis included repeated measures analysis of covariance (corrected for dietary VitD intake) and linear regression. Results: IL-6 and IL-1Ra serum levels showed overall increases after 13 weeks (p = 0.006 and p < 0.001, respectively). For IL-6 a significant time × treatment interaction (p = 0.046) was observed, with no significant change over time in the active group (p = 0.155) compared to control (significant increase p = 0.012). IL-8 showed an overall significant decrease (p = 0.03). The change in pre-albumin was a significant predictor for changes in IL-6 after 13 weeks. Conclusions: We conclude that 13 weeks of nutritional supplementation with VitD and leucine-enriched whey protein may attenuate the progression of CLIP in older sarcopenic persons with mobility limitations.

KW - Aged

KW - Aged, 80 and over

KW - Dietary Supplements

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Interleukin 1 Receptor Antagonist Protein/blood

KW - Interleukin-6/blood

KW - Leucine/pharmacology

KW - Male

KW - Middle Aged

KW - Mobility Limitation

KW - Muscle, Skeletal/drug effects

KW - Sarcopenia/blood

KW - Vitamin D/pharmacology

KW - Whey Proteins/pharmacology

UR - http://www.scopus.com/inward/record.url?scp=85065308767&partnerID=8YFLogxK

U2 - 10.1007/s40520-019-01208-4

DO - 10.1007/s40520-019-01208-4

M3 - Article

VL - 31

SP - 845

EP - 854

JO - Aging Clinical and Experimental Research

JF - Aging Clinical and Experimental Research

SN - 1594-0667

IS - 6

ER -

ID: 46179551